MangoRx vs Shed: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

52 providers verified independently·Independent research·How we rank →

Visit Shed - our pick of these two→or find your match

Shed beats MangoRx overall, scoring 7.8/10 vs 7.5/10. Shed is more affordable at $199/mo vs $299/mo. Choose MangoRx for needle-phobic users who want oral-only glp-1 tablets from a . Choose Shed for users who want fast delivery and a streamlined compounded gl.

A side-by-side look at MangoRx and Shed to help you decide. We compare them on:

•Starting price per month
•Our overall score, out of 10
•Medication type, brand-name or compounded
•Whether they accept insurance
•Who each one is best for

MangoRx

#26 of 52

7.5/10

Multi-service telehealth platform offering compounded GLP-1 alongside other health services.

Visit MangoRx

Higher Rated

Shed

#15 of 52

7.8/10

Newer GLP-1 provider focused on speed and simplicity, fast approvals, fast shipping, and a clean user experience at a competitive price point.

Visit Shed

Feature	MangoRx	Shed
Our Score	7.5/10	7.8/10
Starting Price	$299/mo	$199/mo
Medication Type	Compounded	Both
Insurance Accepted	No	No
Best For	Needle-phobic users who want oral-only GLP-1 tablets from a publicly traded company	Users who want fast delivery and a streamlined compounded GLP-1 experience
Ranking	#26	#15
Get started	Visit MangoRx	Visit Shed

Pros & Cons Compared

MangoRx

Pros

+Oral dissolving tablets exclusively, zero injections for any GLP-1 option
+Publicly traded on NASDAQ (MGRX), SEC-required financial transparency that private competitors can't match
+Semaglutide tablet includes Vitamin B6 to help reduce nausea during treatment
+Free 100% online consultation with no video call required

Cons

−Oral semaglutide at $299/mo runs 2-3x injectable alternatives ($99-149/mo). The premium only makes sense if needles are a hard no for you.
−Early-stage public company with limited revenue; the same SEC filings that provide transparency also show the financial uncertainty reflected in the stock.
−Oral tablets are the only format, with no injectable option if you want higher bioavailability. If you may switch to injections later, pick a platform that carries both.

Shed

Pros

+Industry-leading delivery speed, most patients receive medication within 2-3 days of enrollment
+$199/mo is competitively priced for an all-inclusive compounded program with good support
+Streamlined onboarding with no video call, approved and shipped faster than most competitors
+Clean, modern UX with real-time shipping tracking and easy provider messaging

Cons

−The core $199 program is compounded semaglutide and tirzepatide; brand-name access runs through a separate $99/mo pathway subscription with medication billed at pharmacy rates on top
−Newer company (founded 2024) with limited long-term track record and outcome data; the 4.6/5 Trustpilot rating across 766 reviews is the strongest early evidence available
−No insurance billing and no FSA/HSA superbills currently available
−Clinical support is responsive (replies typically within 24 hours) but less proactive than premium platforms; a $49.99/mo premium coaching add-on covers those who want higher touch

Our Verdict

Shed edges out MangoRx with a score of 7.8/10 vs 7.5/10. If budget is your priority, Shed starts at $199/mo compared to MangoRx's $299/mo. Shed offers both brand-name and compounded medications, giving you more flexibility. Choose MangoRx if you want: needle-phobic users who want oral-only glp-1 tablets from a publicly traded company. Choose Shed if you want: users who want fast delivery and a streamlined compounded glp-1 experience.

Still undecided? Editor's Featured Pick

Yucca Health

$146/mo · 7.7/10 · Compounded

If neither MangoRx nor Shed feels like the right fit, our featured pick across all 52 GLP-1 telehealth providers is Yucca Health. It is not the highest-scored provider in our full rankings. We feature it for its low-friction value: a flat $146/mo that stays the same at every dose.

Visit Yucca Health→Read our full Yucca Health review